Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gallium Ga 68 satoreotide tetraxetan

A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide that is linked via the chelating agent tetraxetan (dodecanetetraacetic acid; DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68 satoreotide tetraxetan binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate can be used to quantify tumor uptake of satoreotide using PET/CT. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:68Ga-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]
68Ga-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2
68Ga-DOTA-JR11
gallium Ga 68 DOTA-JR11
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search